16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nutritional supplementation and dietary restriction in the resolution of enthesitis-related arthritis

      case-report
      1 , 2
      JRSM Short Reports
      Royal Society of Medicine Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A case of a 14-year-old girl with a 2-year history of peripheral and sacroiliac joint pain and gastrointestinal symptoms, secondary to enthesitis-related arthritis, is presented along with the management. Introduction Previously considered a chronic condition, enthesitis-related arthritis – a type of juvenile idiopathic arthritis – may in some cases represent a sensitivity-related illness and thus respond to antigenic avoidance and remediation of biochemistry. Enthesitis-related arthritis is a rare but serious cause of childhood disability and chronic pain that often leads to continuing complications in adult life. Forming a small (1–16%) subset of children with juvenile idiopathic arthritis, 1,2 enthesitis-related arthritis patients typically experience enthesitis and asymmetrical hip and lower extremity arthritis. 3–5 Common systemic features include acute iritis 6 and subclinical inflammatory bowel disease (IBD), 7 while symptomatic cardiac myopathies and pulmonary parenchymal disease occur less commonly. 1,8 Unlike adult-onset spondyloarthropathies, sacroiliitis in enthesitis-related arthritis tends to present years after disease onset. 8 To meet International League of Associations for Rheumatology (ILAR) classification for enthesitis-related arthritis, patients must have (1) arthritis and enthesitis; or (2) arthritis or enthesitis with at least two of the following: Acute, symptomatic anterior uveitis; Sacroiliac joint or lumbosacral pain; Male gender and age over 6 years; HLA-B27 genotype; First-degree relative with history of ankylosing spondylitis (AS), enthesitis-related arthritis, sacroiliitis with IBD, Reiter's syndrome, or acute anterior uveitis. Exclusion criteria for enthesitis-related arthritis include systemic juvenile idiopathic arthritis, psoriasis, or two positive findings of IgM rheumatoid factor occurring three months apart. 9 Genetic factors are particularly significant in enthesitis-related arthritis as 80% of cases are found to be HLA-B27 positive. 1 Possessing a HLA-B27 genotype confers a 20-fold increase in spondylopathy risk in Caucasian populations 10 and also increases risk of enthesitis-related arthritis progression to AS. 11 Moreover, HLA-B27 is implicated in cardiac, 12 pulmonary 10 and malignant 13 complications of spondylopathies. While multiple mechanisms have been proposed for the role of HLA-B27 allotypes in triggering autoimmunity, 10 research is still inconclusive on the exact pathophysiology. Extensive work has been done on the extent to which genetics influence juvenile idiopathic arthritis and spondylopathies 14,15 but environmental parameters remain largely unexplored due to the relative rarity of the condition and the continuing re-classification of juvenile idiopathic arthritis. Preliminary evidence implicates the absence of breastfeeding, maternal smoking, 16 and infection – particularly streptococcus and Epstein-Barr virus – in the development of juvenile idiopathic arthritis, 17 but further inquiry is needed. Although children with juvenile idiopathic arthritis are known to be at risk for malnutrition, nutritional studies have focused on BMI rather than specific biochemical deficiencies. 18 Management of enthesitis-related arthritis Non-steroidal anti-inflammatory drugs (NSAIDs) remain the first-line treatment for enthesitis-related arthritis, while metrotrexate and sulfasalazine are often introduced in the early stages for better symptom control. 19 AntiTNF-alpha biologics, particularly etanercept, 3 are increasingly used in paediatric autoimmune disease. While generally well-tolerated, gastrointestinal symptoms including nausea, vomiting and abdominal pain are a significant adverse effect of all of these options, 3,20 often complicated by inflammation due to disease activity. 21 Beyond gastrointestinal symptoms, each of these medications has significant side-effect profiles. NSAIDs are also associated with nephrotoxicity, headaches and behavioural changes, while methotrexate may cause (largely reversible) liver toxicity. 4,22,23 Other reported adverse effects of methotrexate include loss of appetite, alopecia, malaise, leucopenia, 19,24 and one case each of intestinal sprue 25 and skin toxicity. 26 Sulfasalazine may cause hepatitis, nephritis, 27 and haematologic abnormalities, 28 although these are all uncommon. 29 Meanwhile, antiTNF-alpha agents have been recently correlated to higher incidences of cancer in adults 30 as well as paediatric malignancy. 31 Although autoimmunity confers an innate predisposition to malignancy, genotoxic effects from antiTNF-alpha therapy in juvenile idiopathic arthritis have been shown to extend beyond pre-existing DNA damage. 32 Rarer events include possible increased occurrence of Crohn's disease with etanercept (although no conclusive link has been established). 33 Finally, steroids are avoided when possible, due to the well-known potential effects on bone density, mental health, weight and growth. 34,35 Treatment outcomes vary. Although patients with juvenile idiopathic arthritis often achieve high educational and employment levels, 36 overall quality of life is most dependent on disease subtype, activity and progression. 37 One-third of juvenile idiopathic arthritis patients experience disease continuing into adulthood with full remission rates ranging from 87% in oligoarthritis to 17–33.4% in enthesitis-related arthritis. 2,38 Unfortunately, progression to AS occurs in 39–75% of enthesitis-related arthritis cases 3,39 even with the advent of new therapies. Though evidence on safety and efficacy is mixed, 40–42 what is certain is that the long-term consequences of new immunosuppressive and biologic therapies in juvenile idiopathic arthritis will not be clear for another generation and caution must be exercised. Case report A 14-year-old girl with a history of enthesitis-related arthritis presented to an environmental medicine clinic, seeking adjunctive therapy for complications of her illness. An extensive history, physical exam, environmental assessment 43 and series of laboratory tests 44 were performed. Sixteen months prior, the previously healthy patient had presented to a family physician with a one-week history of sudden-onset right knee pain. A joint aspirate was inconclusive for viral infection and naproxen was prescribed for pain control. Early investigations showed a positive result for antinuclear antibody and an elevated CRP (result 86.6 mg/L with normal 0–8 mg/L). Results were negative for Streptococcus, Lyme and Bartonella exposure. Family history included ulcerative colitis in her father, and paternal grandfather, although neither had sacroiliitis. Over the next month, symptoms progressed to include stiffness and soreness in her lower back, bilateral knees and hips, right wrist and right first interphalangeal joint, at which point rheumatology was consulted and diagnosed enthesitis-related arthritis, although HLA-B27 testing was not done. Visualizing persistent joint effusions on ultrasound, the rheumatologist began methotrexate and what would become a five-month course of prednisone in addition to Naproxen. Sulfasalazine treatment began 14 months after disease onset, as the patient experienced increasing difficulty swallowing pills. Although the patient noted some improvement with medications, soreness and stiffness remained in her back and affected joints. Intra-articular steroid injections were associated with improved function in her right wrist and thumb, and physiotherapy and occupational therapy were beneficial, but pain continued to limit her participation in sports and school activities. Schoolwork was also difficult as she was right-handed. Significant medication-related nausea and abdominal discomfort were only minimally lessened with antiemetic medication – ondansetron. However, the patient stated that compliance with ondansetron was poor as the sight of any pill became associated with nausea. Moreover, the course of prednisone had resulted in a 20 lb weight gain, about which the adolescent patient was quite self-conscious. While moderately satisfied with conventional treatment, the family regularly sought out alternative therapies such as craniosacral therapy and reflexology; these interventions were felt to be minimally helpful. Medical records from the environmental health clinic revealed that physical exam was unremarkable aside from a high BMI, and exposure history was typical for a North American teenager. However, biochemical analysis showed severe nutritional abnormalities including low serum levels of tryptophan, taurine and glutamic acid, and low blood levels of zinc and copper. Serum levels of sulfate, co-enzyme Q10, alpha-tocopherol, vitamin A, B-carotene, and 25-hydroxy-vitamin D were also markedly low. Toxicant analysis revealed elevated arsenic and mercury levels in whole blood, as well as the presence of two fungal mycotoxins – ochratoxins and tricothecenes in urine testing – suggesting a history of mold exposure. In light of the prednisone exposure, bone density analysis was conducted and found low – normal levels in the patient's hip and spine (total hip z-score –1.2; total spine z-score –0.9). Given the evidence of toxicant bioaccumulation, it was hypothesized that the mechanism for development of enthesitis-related arthritis in this case might be related to epigenetic determinants and sensitivity-related illness 45 – a disease mechanism initially described in the literature by Claudia Miller in a 1996 paper in Toxicology 46 and thought to be mediated primarily through the action of pro-inflammatory cytokines. 45 Accordingly, proposed treatment focused on: (1) removing agents recognized as common antigenic triggers; (2) restoring nutritional adequacy; and (3) intervening to remove the bioaccumulated toxicants such as mycotoxins and other toxic elements. 45 This approach has proven worthwhile with other immune-related conditions. 47 Gluten and casein are commonly linked to sensitivity-related illnesses, 48 and were thus eliminated from the patient's diet along with refined sugar, artificial sweeteners, flavouring agents and corn. Next, initial supplementation focused on vitamin D, zinc, copper, DHA, strontium, vitamin K2, magnesium and probiotics, due to the following indications: Vitamin D deficiencies are linked to autoimmune rheumatic disease in adults, 49 and adequate levels are known to be anti-inflammatory; 50–52 Copper and zinc play significant roles as co-factors in normal immune functioning 53–55 and deficiencies are linked to gut inflammation. 56 Furthermore, copper and zinc deficiencies are associated with rheumatoid arthritis; 57,58 Though evidence for probiotics is not yet conclusive, 59 they may decrease gut inflammation, 60–62 improve arthralgias, 63 and improve gut barrier function. 64 As the combination of steroid treatment and juvenile idiopathic arthritis are known to predispose patients to a higher lifetime risk of osteoporosis, 65,66 a series of agents were targeted at bone health. Studies support the use of strontium, magnesium and vitamin D, and to a lesser extent, vitamin K2 and DHA in increasing osteoblast activity and restoring bone density. 67–73 Zinc and copper are increasingly recognized as important co-factors in preventing osteoporosis as well. 74,75 Within one month, the patient saw significant improvements in function that allowed her to decrease, and then completely discontinue the methotrexate, sulfasalazine, naproxen and ondansetron after six months. At six months, antinuclear antibody testing was repeated and found to be negative, and CRP levels had returned to normal (result 1.0 mg/L), supporting the clinical picture of inactive disease. Two months after discontinuation, the patient reported that her functioning and quality of life were ‘just like before’ the onset of enthesitis-related arthritis, and she was fully participating in gym class without any concerns. She had lost the excess weight, was taking guitar lessons without further wrist or finger symptoms, and found the diet and lifestyle changes ‘more than worth it’ for the health she was experiencing. At 13 months post intervention, the patient remains completely well with no recurrence of symptoms. Follow-up will continue with the environmental health specialist to address the xenobiotics found on toxic elements and mycotoxin analysis – the suspected factors likely involved in the initiation of sensitivity-related illness in this patient. Discussion By the Wallace criteria, true remission of disease cannot be declared until the patient has been completely asymptomatic without medication for 12 months with no active arthritis; no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to juvenile idiopathic arthritis; no active uveitis; normal erythrocyte sedimentation rate (ESR) or CRP and a physician's global assessment of disease activity. 38 As the patient has been asymptomatic for over 12 months, she can be considered to be in full remission as she meets all criteria. Nevertheless, to the authors’ knowledge, this is the first reported case of amelioration of enthesitis-related arthritis symptoms after treatment with dietary changes and nutritional supplementation. While studies have focused on specific areas of nutritional deficiency related to juvenile idiopathic arthritis, 17,18,50,76 no treatment strategy has targeted environmental factors as key to enthesitis-related arthritis and its remission. Still, a growing body of evidence suggests sensitivity-related illness as a mechanism behind many cases of autoimmune disorders. 45 It is unknown to what degree the specific signs and symptoms in this case are the direct result of sensitivity-related inflammation or the secondary result of disordered biology resulting from nutritional deficiency. As maldigestion and malabsorpion are common problems associated with food intolerance resulting from sensitivity-related inflammation, nutritional deficiency ensues – which may account for the malnutrition state in many cases of enthesitis-related arthritis. In the sensitivity-related illness model, a patient's genetic predisposition towards illness is compounded by the accumulation of toxicants, including toxic elements 77,78 and mycotoxins. 79,80 Each toxicant may impact immune system functioning, cumulating in sensitivity towards agents that are typically well-tolerated (such as casein and gluten). In response, autoantibodies form 45,78 to tissues including that of the joints and the gut, 81 leading to the presenting symptoms. Mycotoxins 80 and medications 59 alike may be determinants in gut inflammation. Inflammation leads to impairment in absorption of nutrients necessary for healthy immune function and excretion of toxic substances (Table 1), further worsening symptoms. 45,46,82,83 Table 1 Micronutrient deficiencies identified in the patient Deficiencies Significance Coenzyme Q10 Electron transport chain; ATP production in aerobic respiration Sulphate Glutathione production, allowing for heavy metal detoxification through direct conjugation, free radical neutralization, antioxidant properties 84 Tryptophan Production of serotonin, melatonin, and endogenous source of niacin Taurine Anti-inflammatory properties, antioxidant; blood pressure regulation 85 Glutamic acid Neurotransmitter Alpha-tocopherol Antioxidant; 86 inhibits mast cell and eosinophil proliferation 87 Vitamin A/Beta-carotene Anti-inflammatory; 88,89 increases Th2 response, decreases Th1 87 Although enthesitis-related arthritis is not usually treated as a sensitivity-related illness, cases of SLE 90 and of polyarticular juvenile idiopathic arthritis 45 have been reported that are either result from, or are resolved through environmental manipulation. While more rigorous study is needed to elucidate the pathways behind the development of enthesitis-related arthritis and to derive consensus conclusions that can be generalized, individual patients may benefit from an environmental medicine approach to their disease. Although one case is insufficient to draw firm conclusions as spontaneous remission is possible, the complete resolution of signs and symptoms occurring within short order after directed interventions were commenced suggests that such an approach warrants further investigation in other patients. Conclusion In this case report, a patient with a two-year history of enthesitis-related arthritis experienced a total resolution of symptoms after avoiding certain inciting antigens and correcting her nutritional deficiencies. Although the conventional approach to enthesitis-related arthritis manages to control patient symptoms and maintain function, years of chronic disease and reliance on medications is not ideal if remission is possible with less toxic measures. Enforcing dietary changes and taking required supplements to address specific nutritional deficiencies requires a high level of commitment on the part of patients and their families, but may offer a better quality of life than the current standard of care. Thus, prior to commencing potentially toxic pharmaceutical interventions, the authors suggest that it is reasonable to consider a detailed assessment and remediation of nutritional biochemistry; an eight-week trial of avoidance of common inciting antigens; and exploration and management of any underlying bio-accumulated toxicant load resulting from adverse environmental exposures. DECLARATIONS Competing interests None declared Funding None Ethical approval Written consent to publication has been obtained from the patient or next of kin Guarantor SJG Contributorship Both authors contributed equally Acknowledgements None Reviewer Gerry Schwalfenberg

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Vitamin E: function and metabolism.

          Although vitamin E has been known as an essential nutrient for reproduction since 1922, we are far from understanding the mechanisms of its physiological functions. Vitamin E is the term for a group of tocopherols and tocotrienols, of which alpha-tocopherol has the highest biological activity. Due to the potent antioxidant properties of tocopherols, the impact of alpha-tocopherol in the prevention of chronic diseases believed to be associated with oxidative stress has often been studied, and beneficial effects have been demonstrated. Recent observations that the alpha-tocopherol transfer protein in the liver specifically sorts out RRR-alpha-tocopherol from all incoming tocopherols for incorporation into plasma lipoproteins, and that alpha-tocopherol has signaling functions in vascular smooth muscle cells that cannot be exerted by other forms of tocopherol with similar antioxidative properties, have raised interest in the roles of vitamin E beyond its antioxidative function. Also, gamma-tocopherol might have functions apart from being an antioxidant. It is a nucleophile able to trap electrophilic mutagens in lipophilic compartments and generates a metabolite that facilitates natriuresis. The metabolism of vitamin E is equally unclear. Excess alpha-tocopherol is converted into alpha-CEHC and excreted in the urine. Other tocopherols, like gamma- and delta-tocopherol, are almost quantitatively degraded and excreted in the urine as the corresponding CEHCs. All rac alpha-tocopherol compared to RRR-alpha-tocopherol is preferentially degraded to alpha-CEHC. Thus, there must be a specific, molecular role of RRR-alpha-tocopherol that is regulated by a system that sorts, distributes, and degrades the different forms of vitamin E, but has not yet been identified. In this article we try to summarize current knowledge on the function of vitamin E, with emphasis on its antioxidant vs. other properties, the preference of the organism for RRR-alpha-tocopherol, and its metabolism to CEHCs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Vitamin D and autoimmunity: new aetiological and therapeutic considerations.

            Vitamin D is frequently prescribed by rheumatologists to prevent and treat osteoporosis. Several observations have shown that vitamin D inhibits proinflammatory processes by suppressing the enhanced activity of immune cells that take part in the autoimmune reaction. Moreover, recent evidence strongly suggests that vitamin D supplementation may be therapeutically beneficial, particularly for Th1-mediated autoimmune disorders. Some reports imply that vitamin D may even be preventive in certain disorders such as multiple sclerosis and diabetes type 1. It seems that vitamin D has crossed the boundaries of calcium metabolism and has become a significant factor in a number of physiological functions, specifically as a biological inhibitor of inflammatory hyperactivity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Role of nutritional zinc in the prevention of osteoporosis.

              Zinc is known as an essential nutritional factor in the growth of the human and animals. Bone growth retardation is a common finding in various conditions associated with dietary zinc deficiency. Bone zinc content has been shown to decrease in aging, skeletal unloading, and postmenopausal conditions, suggesting its role in bone disorder. Zinc has been demonstrated to have a stimulatory effect on osteoblastic bone formation and mineralization; the metal directly activates aminoacyl-tRNA synthetase, a rate-limiting enzyme at translational process of protein synthesis, in the cells, and it stimulates cellular protein synthesis. Zinc has been shown to stimulate gene expression of the transcription factors runt-related transcription factor 2 (Runx2) that is related to differentiation into osteoblastic cells. Moreover, zinc has been shown to inhibit osteoclastic bone resorption due to inhibiting osteoclast-like cell formation from bone marrow cells and stimulating apoptotic cell death of mature osteoclasts. Zinc has a suppressive effect on the receptor activator of nuclear factor (NF)-kappaB ligand (RANKL)-induced osteoclastogenesis. Zinc transporter has been shown to express in osteoblastic and osteoclastic cells. Zinc protein is involved in transcription. The intake of dietary zinc causes an increase in bone mass. beta-Alanyl-L: -histidinato zinc (AHZ) is a zinc compound, in which zinc is chelated to beta-alanyl-L: -histidine. The stimulatory effect of AHZ on bone formation is more intensive than that of zinc sulfate. Zinc acexamate has also been shown to have a potent-anabolic effect on bone. The oral administration of AHZ or zinc acexamate has the restorative effect on bone loss under various pathophysiologic conditions including aging, skeletal unloading, aluminum bone toxicity, calcium- and vitamin D-deficiency, adjuvant arthritis, estrogen deficiency, diabetes, and fracture healing. Zinc compounds may be designed as new supplementation factor in the prevention and therapy of osteoporosis.
                Bookmark

                Author and article information

                Journal
                JRSM Short Rep
                SHORTS
                rsmshorts
                JRSM Short Reports
                Royal Society of Medicine Press
                2042-5333
                April 2011
                18 April 2011
                : 2
                : 4
                : 32
                Affiliations
                [1 ]simpleSchool of Human Development, University of Alberta , Edmonton, Canada
                [2 ]simpleFaculty of Medicine and Dentistry, University of Alberta , Edmonton, Canada
                Author notes
                Correspondence to: Stephen J Genuis. Email: sgenuis@ 123456ualberta.ca
                Article
                SHORTS-11-012
                10.1258/shorts.2011.011012
                3085976
                21541080
                8776a893-dc33-44ac-b6cd-84bd15f3e971
                © 2011 Royal Society of Medicine Press

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by-nc/2.0/), which permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                122
                168
                270
                Case Report

                Medicine
                Medicine

                Comments

                Comment on this article